JP6873490B2 - 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置 - Google Patents

糖尿病関連バイオマーカーおよび糖尿病関連状態の処置 Download PDF

Info

Publication number
JP6873490B2
JP6873490B2 JP2018539256A JP2018539256A JP6873490B2 JP 6873490 B2 JP6873490 B2 JP 6873490B2 JP 2018539256 A JP2018539256 A JP 2018539256A JP 2018539256 A JP2018539256 A JP 2018539256A JP 6873490 B2 JP6873490 B2 JP 6873490B2
Authority
JP
Japan
Prior art keywords
diabetes
biomarker
panel
optionally
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500619A (ja
JP2019500619A5 (enExample
Inventor
ジア，ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019500619A publication Critical patent/JP2019500619A/ja
Publication of JP2019500619A5 publication Critical patent/JP2019500619A5/ja
Application granted granted Critical
Publication of JP6873490B2 publication Critical patent/JP6873490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
JP2018539256A 2015-10-18 2016-10-18 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置 Active JP6873490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562243131P 2015-10-18 2015-10-18
US62/243,131 2015-10-18
PCT/US2016/057538 WO2017070114A2 (en) 2015-10-18 2016-10-18 Diabetes-related biomarkers and treatment of diabetes-related conditions

Publications (3)

Publication Number Publication Date
JP2019500619A JP2019500619A (ja) 2019-01-10
JP2019500619A5 JP2019500619A5 (enExample) 2019-11-21
JP6873490B2 true JP6873490B2 (ja) 2021-05-19

Family

ID=58557962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539256A Active JP6873490B2 (ja) 2015-10-18 2016-10-18 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置

Country Status (4)

Country Link
US (2) US10884005B2 (enExample)
EP (1) EP3362060A4 (enExample)
JP (1) JP6873490B2 (enExample)
WO (1) WO2017070114A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115236166A (zh) 2016-05-29 2022-10-25 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法
WO2019018656A1 (en) * 2017-07-19 2019-01-24 Ironwood Pharmaceuticals, Inc. EFFICACY OF A DOSAGE FORM OF BILIARY ACID SEQUESTERING AGENT WITH GASTRIC RETENTION
US12313634B2 (en) 2017-11-20 2025-05-27 Zora Biosciences Oy Methods for prediction and early detection of diabetes
KR102122988B1 (ko) * 2018-07-31 2020-06-16 한국과학기술연구원 간헐적 단식 예후 분석을 위한 바이오마커
CN109298115B (zh) * 2018-10-19 2020-07-28 深圳市绘云生物科技有限公司 生物样品中多种代谢物定量检测方法及代谢芯片
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
CN112326948B (zh) * 2020-11-09 2023-08-11 上海市内分泌代谢病研究所 用于预测糖尿病的生物标记物、试剂盒及其使用方法
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법
US12100484B2 (en) 2021-11-01 2024-09-24 Matterworks Inc Methods and compositions for analyte quantification
US11754536B2 (en) 2021-11-01 2023-09-12 Matterworks Inc Methods and compositions for analyte quantification
EP4437319A4 (en) * 2021-11-01 2025-11-26 Matterworks Inc METHODS AND COMPOSITIONS FOR THE QUANTIFICATION OF ANALYTES
CN115023608B (zh) * 2021-11-30 2024-01-19 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114166977B (zh) * 2022-01-24 2022-06-21 杭州凯莱谱精准医疗检测技术有限公司 预测妊娠个体血糖值的系统
CN116519812A (zh) 2022-01-24 2023-08-01 杭州凯莱谱精准医疗检测技术有限公司 生物标志物在制备妊娠糖尿病诊断试剂中的用途
CN114354827A (zh) * 2022-03-21 2022-04-15 天津云检医疗器械有限公司 代谢标志物及其在制备2型糖尿病的风险预测试剂盒中的应用和试剂盒
CN118566364A (zh) * 2024-05-20 2024-08-30 首都医科大学附属北京胸科医院 一组预测新型冠状病毒感染危重患者及预后的标志物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
US7001631B2 (en) * 2002-07-30 2006-02-21 Steris Inc. Low temperature sanitization of human pathogens from the surfaces of food and food packaging
WO2010005982A2 (en) * 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
EP2161580A1 (en) * 2008-09-02 2010-03-10 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Biomarkers for identifying subjects predisposed to developing insulin resistance and determining the insulin resistance status
WO2010114897A1 (en) * 2009-03-31 2010-10-07 Metabolon, Inc. Biomarkers related to insulin resistance and methods using the same
JP2013509587A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド 糖尿病のリスクを決定する方法
JP6082328B2 (ja) * 2013-07-31 2017-02-15 株式会社Ｌｓｉメディエンス 胆汁酸同時分析方法

Also Published As

Publication number Publication date
WO2017070114A2 (en) 2017-04-27
EP3362060A2 (en) 2018-08-22
EP3362060A4 (en) 2019-06-19
US20210116467A1 (en) 2021-04-22
WO2017070114A3 (en) 2017-06-08
JP2019500619A (ja) 2019-01-10
US20190285656A1 (en) 2019-09-19
US10884005B2 (en) 2021-01-05

Similar Documents

Publication Publication Date Title
JP6873490B2 (ja) 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
JP6021187B2 (ja) 自閉症の代謝バイオマーカー
Burgess et al. Metabolome-wide association study of primary open angle glaucoma
Klein et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes
CN107427221B (zh) 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
EP3321686B1 (en) Biomarkers related to insulin resistance progression and methods using the same
CN106461685B (zh) 神经酰胺及其在诊断cvd中的应用
EP2546649A2 (en) Biomarkers for fatty liver disease and methods using the same
CN102449161A (zh) 与胰岛素抵抗有关的生物标记和使用该生物标记的方法
Cui et al. Salivary metabolomics reveals that metabolic alterations precede the onset of schizophrenia
JP6158186B2 (ja) インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法
EP3491004B1 (en) Diagnostic methods, therapeutic agents and uses thereof
EP3714273A1 (en) Methods for prediction and early detection of diabetes
Zmyslowska et al. Serum metabolic fingerprinting identified putatively annotated sphinganine isomer as a biomarker of Wolfram syndrome
Morris et al. The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer’s disease
Zeleznik et al. Plasma metabolomics of primary open-angle glaucoma in three prospective US cohorts and the UK Biobank
CN114324902B (zh) 胆固醇稳态的生物标志物及其应用
Cao et al. Intestinal-level anti-inflammatory bioactivities of whole wheat: Rationale, design, and methods of a randomized, controlled, crossover dietary trial in adults with prediabetes
US20240044826A1 (en) Metabolic vulnerability analyzed by nmr
AU2016206265B2 (en) Method for Determining Insulin Sensitivity with Biomarkers
Morris et al. The serum metabolomics signature of Type 2 Diabetes is obscured in Alzheimer’s
CN119470873A (zh) 代谢综合征的生物标志物
Rubbia-Brandt et al. Scientific Program
HK1217516B (en) Biomarkers related to insulin resistance progression and methods using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210414

R150 Certificate of patent or registration of utility model

Ref document number: 6873490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250